Oncotelic Therapeutics, Inc. (OTLC)
- Previous Close
0.0408 - Open
0.0400 - Bid --
- Ask --
- Day's Range
0.0361 - 0.0420 - 52 Week Range
0.0100 - 0.0500 - Volume
22,308 - Avg. Volume
74,853 - Market Cap (intraday)
16.787M - Beta (5Y Monthly) 0.06
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0200 - Earnings Date May 18, 2024 - May 22, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; and CA4P for the treatment of advanced metastatic melanoma; intranasal drug and delivery system for intra-nasal Apomorphine for the treatment of Parkinson's Disease, erectile disfunction, and female sexual disfunction; Artemisinin, a natural derivative from an Asian herb Artemisia Annua; and AI based technologies to enhance the development and commercialization of Artemisinin based products and support technologies. Oncotelic Therapeutics, Inc. is based in Agoura Hills, California.
www.oncotelic.comRecent News: OTLC
Performance Overview: OTLC
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: OTLC
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: OTLC
Valuation Measures
Market Cap
16.79M
Enterprise Value
29.19M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
237.70
Price/Book (mrq)
1.38
Enterprise Value/Revenue
417.00
Enterprise Value/EBITDA
-4.08
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-1.07%
Return on Equity (ttm)
-53.28%
Revenue (ttm)
70k
Net Income Avi to Common (ttm)
-7.9M
Diluted EPS (ttm)
-0.0200
Balance Sheet and Cash Flow
Total Cash (mrq)
170.41k
Total Debt/Equity (mrq)
108.29%
Levered Free Cash Flow (ttm)
-580.54k
Research Analysis: OTLC
Company Insights: OTLC
OTLC does not have Company Insights